Wexford Capital’s Minerva Neurosciences NERV Stock Holding History

Wexford Capital’s Portfolio NERV Stock Details NERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,934	Closed	-$36K	–	293
2020 Q4	$36K	Buy	+1,934	New	+$48.7K	0.01%	284

Other funds holding NERV

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Wexford Capital's NERV Position: Q1 2021 in Review

Wexford Capital sold out of Minerva Neurosciences (NERV) in Q1 2021, closing a stake of 1,934 shares — an estimated $36K sold.

Wexford Capital first reported a position in NERV in Q4 2020 and held it in 1 quarter. The position peaked at $36K in Q4 2020. 72 funds tracked by Wall St. Rank hold NERV as of Q1 2021.

Wexford Capital reported no remaining Minerva Neurosciences position as of Q1 2021 after selling out during the quarter.
Wexford Capital sold 1,934 Minerva Neurosciences shares in Q1 2021, an estimated $36K.
Wexford Capital first reported a position in Minerva Neurosciences in Q4 2020 and held it in 1 quarter.
Wexford Capital's Minerva Neurosciences position peaked at $36K in Q4 2020.
72 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q1 2021.

Based on Wexford Capital's 13F filing for Q1 2021, filed 13 May 2021.